Ocean Biomedical, Inc.

Ocean Biomedical, Inc. (Nasdaq: OCEA) is a clinical-stage biopharmaceutical company that completed its business combination with Aesther Healthcare Acquisition Corp., a blank-check company sponsored by Aesther Healthcare Management, and began trading as a public entity in early 2023. The SPAC vehicle priced its IPO in 2021 and targeted the healthcare and life sciences sector. Ocean Biomedical is focused on developing therapeutics across oncology, infectious disease, and pulmonary fibrosis, drawing on research originating from Brown University. The company filed an 8-K with the SEC on October 12, 2023, under accession number 0001493152-23-037068. Sign up at SpacDesk for full filing history, deal timelines, and real-time data on OCEA and hundreds of other SPAC transactions.